文献速递病毒性肝炎

艾尔巴韦/格拉瑞韦8周与12周治疗初治基因1b型丙肝轻度纤维化:EGALITE随机对照试验

An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
PubMed 文献 · J Infect Dis · 2019-01-01

结论为12周方案高效,8周缩短方案或可用于低病毒载量或无显著NS5A RAS者。

要点

  • 12周格拉瑞韦/艾尔巴韦对初治HCV-1b轻度纤维化患者SVR12达100%。
  • 高病毒载量或基线Y93H RAS>15%者不建议用8周方案。

核心结论

  • 12周格拉瑞韦/艾尔巴韦治疗初治HCV-1b轻度纤维化患者高度有效;8周缩短方案可能适用于低病毒载量或无显著NS5A RAS频率者。

研究设计与样本

  • 开放标签、随机、活性对照试验,纳入初治HCV-1b感染伴轻度纤维化患者,随机分为8周组(n=41)与12周组(n=41),主要终点为治疗后第12周SVR12(HCV RNA<12 IU/mL)。

主要发现

  • 高病毒载量且基线Y93H RAS频率>15%者中,8周组SVR12为40.0%,12周组为100.0%。
  • 全部4例HCV-1b复发者在治疗后第12周Y93H RAS频率均>99%。

关键数值与推荐

  • 主要终点SVR12定义为治疗后第12周HCV RNA<12 IU/mL。
  • 显著NS5A RAS定义为基线Y93H频率>15%。

临床怎么用

  • 初治HCV-1b轻度纤维化可优先选择12周格拉瑞韦/艾尔巴韦方案。
  • 考虑8周缩短方案前应评估基线病毒载量与NS5A Y93H RAS频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive HCV-1-infected patients with mild fibrosis has not been determined. METHODS: Treatment-naive HCV-1b-infected patients with mild fibrosis were randomly assigned to receive 8 (n = 41) or 12 (n = 41) weeks of grazoprevir/elbasvir therapy. The primary end point was a sustained virologic response, defined as an HCV RNA level of < 12 IU/mL, at posttreatment week 12 (SVR12). RESULTS: SVR12 was achieved by 87.8% of patients (36 of 41) in the 8-week arm and 100% (41 of 41) in the 8-week arm of the full-analysis population and by 90.0% (36 of 40) and 100% (41 of 41), respectively, in the per-protocol population (all P = .055). In the 8-week arm, a significantly lower SVR12 rate was observed among patients with a high HCV-1b load, defined as ≥1 500 000 IU/mL (79% vs 100%; P = .042), and among those with a baseline Y93H resistance-associated substitution (RAS) frequency of >15% in HCV nonstructural protein 5A (NS5A; 40.0% vs 97.1%; P = .004). Between-group analysis demonstrated that, among patient with a high HCV-1b load and a baseline Y93H RAS frequency of >15%, those in the 8-week arm had a substantially lower SVR12 rate than those in the 12-week arm (40.0% vs 100.0%). All 4 HCV-1b relapses had a Y93H RAS frequency of >99% at posttreatment week 12. CONCLUSIONS: Twelve weeks of grazoprevir/elbasvir therapy is highly effective for treatment-naive patients with mild fibrosis. A truncated, 8-week grazoprevir/elbasvir regimen might be applied for those with low viral loads or without a significant NS5A RAS frequency. CLINICAL TRIALS REGISTRATION: NCT03186365.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Huang CF, Hung CH, Cheng PN, et al. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis. 2019. PMID: 30957170. doi:10.1093/infdis/jiz154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。